Comparing protein VEGF inhibitors: In vitro biological studies

Biochemical and Biophysical Research Communications

Volumn 408, Issue 2, 2011, Pages 276-281

  Yu, Lanlan ^a   Liang, Xiao Huan ^a   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Antibody; Bevacizumab; Cancer; Ranibizumab; Tumor; VEGF; VEGF receptor; VEGF Trap

Indexed keywords

BEVACIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; OMALIZUMAB; RANIBIZUMAB;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BIOASSAY; BOVINE RETINAL MICROVASCULAR ENDOTHELIAL CELL; CELL MIGRATION; CHEMOTAXIS; COW; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA CELL; RETINA MACULA AGE RELATED DEGENERATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; CATTLE; CELLS, CULTURED; CHEMOTAXIS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

BOVINAE;

EID: 79955661504     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.014     Document Type: Article

References (32)

1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
2. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
3. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990, 8:519-527.
4. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6:1677-1683.
5. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) 2005, 109:227-241.
6. Ferrara N., Mass R.D., Campa C., Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 2007, 58:491-504.
7. Adamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005, 25:111-118.
8. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816.
9. Ferrara N., Damico L., Shams N., Lowman H., Kim R. An anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26:859-870.
10. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
11. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444.
12. Chen Y., Wiesmann C., Fuh G., Li B., Christinger H.W., McKay P., de Vos A.M., Lowman H.B. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 1999, 293:865-881.
13. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-4599.
14. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006, 113:363-372.
15. Davis-Smyth T., Chen H., Park J., Presta L.G., Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 1996, 15:4919-4927.
16. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997, 91:695-704.
17. Ferrara N., Chen H., Davis-Smyth T., Gerber H.-P., Nguyen T.-N., Peers D., Chisholm V., Hillan K.J., Schwall R.H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 1998, 4:336-340.
18. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.-A., Rangell L., Wright B.D., Radtke F., Aguet M., Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999, 126:1149-1159.
19. Malik A.K., Baldwin M.E., Peale F., Fuh G., Liang W.C., Lowman H., Meng G., Ferrara N., Gerber H.P. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 2006, 107:550-557.
20. Wulff C., Wiegand S.J., Saunders P.T., Scobie G.A., Fraser H.M. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 2001, 142:3244-3254.
21. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99:11393-11398.
22. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 2004, 113:1040-1050.
23. Gerber H.P., Wu X., Yu L., Weissman C., Liang X.H., Lee C.V., Fuh G., Olsson C., Damico L., Xie D., Meng Y.G., Gutierrez J., Corpuz R., Li B., Hall L., Rangell L., Ferrando R., Lowman H., Peale F., Ferrara N. Mice expressing a humanized form of VEGF-A may provide insights into safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 2007, 104:3478-3483.
24. Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., Pease L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 1989, 77:61-68.
25. Yu L., Wu X., Cheng Z., Lee C.V., Lecouter J., Campa C., Fuh G., Lowman H., Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest. Ophthalmol. Vis. Sci. 2008, 49:522-527.
26. Gospodarowicz D., Massoglia S., Cheng J., Fujii D.K. Effect of fibroblast growth factor and lipoproteins on the proliferation of endothelial cells derived from bovine adrenal cortex, brain cortex, and corpus luteum capillaries. J. Cell Physiol. 1986, 127:121-136.
27. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 1997, 272:32521-32527.
28. Jager R.D., Mieler W.F., Miller J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358:2606-2617.
29. Brown D.M., Campochiaro P.A., Singh R.P., Li Z., Gray S., Saroj N., Rundle A.C., Rubio R.G., Murahashi W.Y. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117:1124 e1-1133 e1.
30. Campochiaro P.A., Heier J.S., Feiner L., Gray S., Saroj N., Rundle A.C., Murahashi W.Y., Rubio R.G. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117:1102 e1-1112 e1.
31. Ciulla T.A., Rosenfeld P.J. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr. Opin. Ophthalmol. 2009, 20:166-174.
32. Stewart M.W., Rosenfeld P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008, 92:667-668.